Skip to main content
NewslettersWatchlist

Moderna Inc(MRNA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low49.60
Day High52.85
Open:52.61
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
These Are the 5 Worst-Performing Stocks in the S&P 500 With 2024 Almost Over
Motley Fool
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
The Globe and Mail
Pfizer struggles to find new revenue sources as vaccine sales fade, but here’s why investors shouldn’t shy away from its stock
Barchart
Option Volatility And Earnings Report For November 4 - 8
Motley Fool
2 Dividend Stocks to Buy for a Lifetime of Passive Income
Barchart
Stocks Close Higher on Reduced Middle East Risks
Barchart
Stocks Higher on Relief After Israel's Limited Retaliation Reduces Middle East Risks
Motley Fool
How Bad Is This News for Novavax?
Motley Fool
2 Biotech Stocks That Are Screaming Buys This Month
Motley Fool
Is It Time to Buy September's Worst-Performing S&P 500 Stocks?
Motley Fool
3 Surprisingly Underrated Stocks to Buy Right Now
Motley Fool
2 Beaten-Down Stocks to Buy and Hold for a Decade
Motley Fool
Down 13% in 1 Day, Is Moderna Stock in Trouble?
MarketBeat
3 Beaten-Down Stocks Ready for a Comeback
Motley Fool
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Barchart
Stock Index Futures Tread Water With Fed Rate Decision in Focus
Barchart
Stocks Close Little Changed Ahead of Wednesday’s FOMC Decision
Motley Fool
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?
Motley Fool
Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More
Motley Fool
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
Barchart
Stocks Rally on Heightened Speculation about a 50 bp Rate Cut Next Week

Profile

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.